a Novel Dual-Agonist, Mitigates Diabetes-Associated Cognitive Dysfunction: Mechanistic Insights from Multi-Omics Analysis
Obesity and type 2 diabetes mellitus (T2DM) are strongly linked to an increased risk of cognitive decline and dementia. Among antidiabetic therapies, GLP-1 receptor agonists have shown superior cognitive benefits by engaging brain-related pathways. a newly developed dual agonist targeting has demonstrated efficacy in lowering body weight, glucose levels, and obesity-related comorbidities in T2DM patients. Importantly, the influence of mazdutide on cognitive function has not yet been clarified.